Canada based Biolyse Pharma Seeks to Manufacture COVID-19 Vaccines for Low-Income Countries, may test Canada’s compulsory licensing for export law

On March 11th 2021, Biolyse Pharma (“Biolyse”) issued a statement publicly indicating their capacity to manufacture a COVID-19 vaccine and their intent to apply for a compulsory license in Canada. Biolyse is a Canadian manufacturer of cancer drugs based out… Continue Reading

NIH responds to Sachs/Love letter on the Xtandi Bayh-Dole safeguards petition, to say, still reviewing

NIH has sent a letter, dated Dec 1, to Robert Sachs and Clare Love, regarding the longstanding petition to HHS to use the federal government’s rights in the patented inventions for enzalutamide, marketed by Astellas in the USA at prices 3 to… Continue Reading

Letter from 19 groups asking HHS to take action on the ​request that HHS use the federal government rights in patents on the prostate drug enzalutamide, marketed by Astellas under the brand name Xtandi.

Attached is a letter from 19 groups asking HHS Secretary Xavier Becerra to take action on the ​request that HHS use the federal government rights in patents on the prostate drug enzalutamide, marketed by Astellas under the brand name Xtandi.… Continue Reading

Pandemic Treaty negotiations: The Conceptual zero draft for the consideration of the Intergovernmental Negotiating Body at its third meeting

This is what delegates will be discussing at the next INB meeting the week of December 5, 2022, in Geneva. ADVANCE_for_16_November_A_INB3_3_E From the document: “In preparing a conceptual zero draft, the Bureau started by integrating the above-mentioned input into the… Continue Reading

Letter to Secretary of HHS Xavier Becerra regarding Xtandi march-in case from Robert Sachs and Clare Love

SecBecerra-18Nov2022-Sachs-Love-Xtandi November 18, 2022 Xavier Becerra Secretary Department of Health & Human Services Washington, DC Via Email: xavier.becerra@hhs.gov Dear Secretary Becerra: Today marks the one-year anniversary since the undersigned prostate cancer patients petitioned the Department of Health & Human Services… Continue Reading

WIPO patent committee charts a course for the examination of voluntary and compulsory licensing practices during the Covid-19 pandemic

On Friday, 30 September 2022, at the Geneva headquarters of the World Intellectual Property Organization (WIPO), the 34th session of Standing Committee on the Law of Patents (SCP) adopted a future work plan for WIPO’s patent committee on patents and… Continue Reading

166 contracts disclosed in SEC filings include authorizations to use U.S. patents without consent from patent holders

On 12 October 2022, Knowledge Ecology International (KEI) published a briefing note on the U.S. federal government FAR 52.227-1 authorizations (for non voluntary use of patents) disclosed in 166 SEC exhibits. KEI Briefing Note 2022:2, Federal government FAR 52.227-1 authorizations… Continue Reading

Informal, focused consultations (IFCs) on WHO’s pandemic treaty to address: 1) legal matters, 2) equity, 3) IP and access to pandemic response products, and 4) One Health, AMR, Climate and Zoonosis

As part of ongoing WHO negotiations on a pandemic treaty, the WHO secretariat is set to convene four informal, focused consultations (IFCs) on the following themes: 1) legal matters, 2) operationalizing and achieving equity, 3) intellectual property and access to… Continue Reading

7 July 2022: Human Rights Council adopts resolution on right to health resolution with references delinkage, solidarity, global public good, and the transfer of technology and know-how

On Thursday, 7 July 2022, the 40th session of the Human Rights Council (HRC) adopted, by consensus, a resolution on Access to medicines, vaccines and other health products in the context of the right of everyone to the enjoyment of… Continue Reading